These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 38295871

  • 1. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An 18F-SynVesT-1 PET/MR study.
    Li J, Huang Q, Qi N, He K, Li S, Huang L, Pan F, Ren S, Hua F, Huang Y, Guan Y, Guo Q, Zhao J, Xie F.
    J Cereb Blood Flow Metab; 2024 Jul; 44(7):1199-1207. PubMed ID: 38295871
    [Abstract] [Full Text] [Related]

  • 2. Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer's disease.
    Wang J, Huang Q, Chen X, You Z, He K, Guo Q, Huang Y, Yang Y, Lin Z, Guo T, Zhao J, Guan Y, Li B, Xie F.
    Mol Psychiatry; 2024 Sep; 29(9):2799-2809. PubMed ID: 38589563
    [Abstract] [Full Text] [Related]

  • 3. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH.
    JAMA Neurol; 2018 Oct 01; 75(10):1215-1224. PubMed ID: 30014145
    [Abstract] [Full Text] [Related]

  • 4. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F]SynVesT-1.
    Xiao L, Xiang S, Chen C, Zhu H, Zhou M, Tang Y, Feng L, Hu S.
    Psychiatry Clin Neurosci; 2024 Aug 01; 78(8):456-467. PubMed ID: 38804583
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O.
    JAMA Neurol; 2020 Aug 01; 77(8):955-965. PubMed ID: 32391858
    [Abstract] [Full Text] [Related]

  • 7. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease.
    Zhang J, Chen H, Wang J, Huang Q, Xu X, Wang W, Xu W, Guan Y, Liu J, Wardlaw JM, Deng Y, Xie F, Li B.
    Alzheimers Dement; 2024 Jun 01; 20(6):3931-3942. PubMed ID: 38648354
    [Abstract] [Full Text] [Related]

  • 8. APOE ε4 is associated with decreased synaptic density in cognitively impaired participants.
    He K, Li B, Wang J, Wang Y, You Z, Chen X, Chen H, Li J, Huang Q, Guo Q, Huang YH, Guan Y, Chen K, Zhao J, Deng Y, Xie F.
    Alzheimers Dement; 2024 May 01; 20(5):3157-3166. PubMed ID: 38477490
    [Abstract] [Full Text] [Related]

  • 9. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.
    Wang J, Huang Q, He K, Li J, Guo T, Yang Y, Lin Z, Li S, Vanderlinden G, Huang Y, Van Laere K, Guan Y, Guo Q, Ni R, Li B, Xie F.
    Alzheimers Dement; 2024 Jun 01; 20(6):3876-3888. PubMed ID: 38634334
    [Abstract] [Full Text] [Related]

  • 10. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage; 2017 Aug 15; 157():448-463. PubMed ID: 28587897
    [Abstract] [Full Text] [Related]

  • 11. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck CH.
    Alzheimers Dement; 2020 Jul 15; 16(7):974-982. PubMed ID: 32400950
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.
    Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roé-Vellvé N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M.
    Alzheimers Res Ther; 2022 Jul 27; 14(1):105. PubMed ID: 35897078
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
    Cousins O, Schubert JJ, Chandra A, Veronese M, Valkimadi P, Creese B, Khan Z, Arathimos R, Hampshire A, Rosenzweig I, Ballard C, Corbett A, Aasland D, Velayudhan L, O'Neill M, Collier D, Awais R, Sander K, Årstad E, Howes O, Turkheimer F, Hodges A.
    J Neuroinflammation; 2023 Nov 21; 20(1):272. PubMed ID: 37990275
    [Abstract] [Full Text] [Related]

  • 20. Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease.
    Teng E, Ward M, Manser PT, Sanabria-Bohorquez S, Ray RD, Wildsmith KR, Baker S, Kerchner GA, Weimer RM.
    Neurobiol Aging; 2019 Sep 21; 81():138-145. PubMed ID: 31280117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.